Ibio, Inc. (IBIO) Stock Price & Analysis
Ibio, Inc. (IBIO) rose 2.14% to USD 1.43 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
IBIO last closed at USD 1.4; the session ranged USD 1.31–1.47 on volume of 1,210,051 shares. Market capitalization is $71.04M, with a 52-week range of USD 0.56–3.82 (NCM). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 1.43 |
|---|---|
| Change | ▲ 2.14% (up) |
| Previous Close | USD 1.4 |
| Open | USD 1.41 |
| Day Range | USD 1.31 – 1.47 |
| 52-Week Range | USD 0.56 – 3.82 |
| Volume | 1,210,051 shares |
| Market Cap | $71.04M |
| Exchange | NCM |
Technical Analysis (IBIO)
Nexqual's technical model rates IBIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.46 (neutral) |
| vs SMA50 | Below (USD 1.63) |
| MACD | -0.08 (negative) |
Analyst Ratings (IBIO)
Wall Street analysts rate IBIO "None" based on 8 analysts, with a mean price target of USD 5.4 (range USD 4.2–7), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 5.4 |
| High Target | USD 7 |
| Low Target | USD 4.2 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (IBIO)
| EPS Estimate | USD -0.06 |
|---|---|
| Revenue Estimate | $66,670 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.09 vs est -0.07 ▼ miss |
| 2025-09-30 | USD -0.11 vs est -0.07 ▼ miss |
| 2025-06-30 | USD -0.32 vs est -0.37 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (IBIO)
| Total Revenue | $300,000 |
|---|---|
| Gross Margin | +100.00% |
| Operating Margin | -9653.00% |
| Profit Margin | +0.00% |
| ROE | -62.09% |
| Debt / Equity | 3 |
| Current Ratio | 11.88 |
| Total Cash | $74.80M |
| Total Debt | $2.33M |
| Free Cash Flow | $-15.24M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (IBIO)
Nexqual rates Ibio, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Strong — Revenue +78% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $75M cash vs $2M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$15M, burning cash |
| Efficiency | Critical — ROE -62%, ROA -34.5% |
Ownership (IBIO)
| Insider Ownership | +1.71% |
|---|---|
| Institutional Ownership | +48.61% |
| Shares Outstanding | 49.68M |
| Float | 45.47M |
| Short % of Float | +9.50% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (IBIO)
Ibio, Inc. is led by Martin B. Brenner D.V.M. (age 55), CEO, Chief Scientific Officer & Director, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO, Chief Scientific Officer & Director | Martin B. Brenner D.V.M. (age 55) |
|---|---|
| Chief Financial Officer | Felipe Duran (age 46) |
| Director of Research and Early Development | Cory Schwartz |
Major Backers & Investors (IBIO)
Notable institutional backers of Ibio, Inc. include Affinity Asset Advisors, Llc, Frazier Life Sciences Management, L.P. , EcoR1 Capital, LLC, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Affinity Asset Advisors, Llc | 6.25% |
| Frazier Life Sciences Management, L.P. | 3.93% |
| EcoR1 Capital, LLC | 3.19% |
| Millennium Management | 3.12% |
| Logos Global Management LP | 2.62% |
| Balyasny Asset Management LP | 2.03% |
| Ikarian Capital, LLC | 1.93% |
| Citadel | 1.93% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.38% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
From Ibio, Inc.'s Latest SEC 10-K Filing (filed 2025-09-05)
Key Strengths & Strategy (as disclosed to the SEC)
- iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.
- The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.
- Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies.
- In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 3.13% |
| TNXP | Tonix Pharmaceuticals Holding C | USD 9.88 | ▼ 6.7% |
| CODX | Co-Diagnostics, Inc. | USD 2.1 | ▼ 7.89% |
| INO | Inovio Pharmaceuticals, Inc. | USD 0.97 | ▼ 8.49% |
| SRNE | Sorrento Therapeutics, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.